Cancer Clinical Trials

Breast Cancer

PACCT-1: Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: TAILORx Trial

• Principal Investigator: Robert Cooper, MD
• Eastern Cooperative Oncology Group

Read More

 
 

E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

• Principal Investigator: Robert Cooper, MD
• Eastern Cooperative Oncology Group

Read More

 

B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

• Principal Investigator: Robert Kloss, MD
• CTSU: NSABP (National Surgical Adjuvant Breast and Bowel Project) 

Read More

  

Colon Cancer

E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

• Principal Investigator: Robert Cooper, MD
• Eastern Cooperative Oncology Group

Read More

 

C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5- FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

• Principle Investigator: Robert Kloss, MD
• CTSU: CALGB (Cancer and Leukemia Group B)

Read More

 

Kidney (Renal) Cancer 

E2805: ASSURE: Adjuvant Sunitinib or Sorafenib for Unfavorable Renal Cell Carcinoma

• Principal Investigator: Robert Cooper, MD
• ECOG (Eastern Cooperative Oncology Group)

Read More

 

Lung Cancer

S0424: Molecular Epidemiology Case-Series Study of Non Small cell lung cancer in smoking and non-smoking women and men, Department of Oncology

• Principal Investigator: Robert Kloss, MD
• CTSU: SWOG (Southwest Oncology Group)

Read More

 

E4508: Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-based Therapy

• Principal Investigator: Robert Cooper, MD
• ECOG (Eastern Cooperative Oncology Group)

Read More

 

109439 “Magrit” A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive Non-Small Cell Lung Cancer

• Principal Investigator: Shawn Tittle, MD
• Glaxo/Smith-Kline

 

A4021032:A Phase 2, Randomized, Open Label Study Of Figitumumab (Cp 751,871)Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer

• Principal Investigator: Vincent Rella, MD
• PFIZER

 

Multiple Myeloma 

S0777: A Randomized Phase III Trial Of Lenalidomide (Revlimid) And Low Dose Dexamethasone Versus Bortezomib (Velcade), Lenalidomide (Revlimid) And Low Dose Dexamethasone For Induction, In Patients With Previously Untreated Multiple Myeloma Without An Intent For Immediate Autologous Stem Cell Transplant

• Principal Investigator: Robert Kloss, MD
• CTSU: SWOG (Southwest Oncology Group)

Read More

 

Ovarian Cancer

GOG 0252: A Phase III Clinical Trial Of Bevacizumab With IV Versus IP Chemotherapy In Ovarian, Fallopian Tube, And Primary Peritoneal Carcinoma

• Principal Investigator: Robert Kloss, MD
• CTSU: GOG (Gynecology Oncology Group)

Read More

 

Skin Cancer

E1697: Phase III Randomized Study of Four Weeks High Dose IFN-α2b in Stage T_2bN₀, T_3a-bN₀, T_4a-bN₀, and T_1-4, N_{1a, 2a} (microscopic) Melanoma

• Principal Investigator: Robert Cooper, MD
• ECOG (Eastern Cooperative Oncology Group)

Read More